Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2027-06-14
Target enrollment:
Participant gender:
Summary
This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of
patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the
safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute
myeloid leukemia.